Genetic Technologies Announces Record Number of BREVAGen(TM) Tests
Genetic Technologies Limited (NASDAQ: GENE) announces that a record number of BREVAGen™ test samples were received during the quarter ended June 30, 2013. Total patient samples received during the quarter was 599, representing growth of more than 48% over the preceding March quarter, demonstrating a significant increasing trend in market traction.
Total BREVAGen™ test samples received during the 2013 financial year was 1,547, representing growth of more than 272% over the preceding 2012 financial year.
Encouragingly, the quarter on quarter percentage growth in the number of BREVAGen™ samples received has been progressively increasing in each of the eight completed quarters since the test was launched in the U.S. market in July 2011. Further, the samples currently being received are generated from a broad mix of U.S. geographical sales territories, demonstrating the growing acceptance of the test across the wider market.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.